Candida auris is an emerging multidrug-resistant yeast that can cause serious invasive infections. Accurate and rapid assessment of antifungal resistance is important for effective patient management. A novel and highly accurate diagnostic platform was established for rapid identification of ERG11 mutations conferring azole resistance and FKS1 mutations associated with echinocandin resistance in C. auris. Using allele-specific molecular beacons and DNA melting curve analysis following asymmetric PCR, a duplex ERG11 assay and a simplex FKS1 HS1 assay were developed to identify the most prominent resistance-associated mutations (Y132F and K143R in ERG11; S639F in FKS1 HS1) within 2 h. Assays were validated by testing a blinded panel of 94 C. auris clinical isolates. The molecular diagnostic results from the assays were 100% concordant with DNA sequencing results. This platform has the potential to overcome the deficiencies of existing in vitro susceptibility-based assays to identify azole and/or echinocandin resistant C. auris, and thus, it holds promise as a surrogate diagnostic method to direct antifungal therapy more effectively.
https://ift.tt/2qv8iDG
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου